Emerging problems in the treatment of pediatric community-acquired pneumonia

References

• Esposito S, Principi N. Pneumococcal vaccines and the prevention of community-acquired pneumonia. Pulm Pharmacol Ther. 2015;32:124–129.
   PubMed Web of Science ®Google Scholar
• Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302–317.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Management of severe community-acquired pneumonia of children in developing and developed countries. Thorax. 2011;66:815–822.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Pneumonia. Available at: http://www.who.int/mediacentre/factsheets/fs331/en/ Accessed on: January 20, 2018.
   Google Scholar
• World Health Organization (WHO). Epidemiology and etiology of childhood pneumonia. Available at: http://www.who.int/bulletin/volumes/86/5/07-048769-table-T1.html. Accessed on: January 20, 2018.
   Google Scholar
• Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. Children N Engl J Med. 2015;372:835–845.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Revised WHO classification and treatment of childhood pneumonia at health facilities. Available at: http://www.who.int/maternal_child_adolescent/documents/child-pneumonia-treatment/en/. Accessed on: January 20, 2018
   Google Scholar
• Korppi M, Don M, Valent F, et al. The value of clinical features in differentiating between viral, pneumococcal and atypical bacterial pneumonia in children. Acta Paediatr. 2008;97:943–947.
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Biomarkers in pediatric community-acquired pneumonia. Int J Mol Sci. 2017;18:pii: E447.
   Web of Science ®Google Scholar
• Williams GJ, Macaskill P, Kerr M, et al. Variability and accuracy in interpretation of consolidation on chest radiography for diagnosing pneumonia in children under 5 years of age. Pediatr Pulmonol. 2013;48:1195–2000.
   PubMed Web of Science ®Google Scholar
• Wallihan R, Ramilo O. Community-acquired pneumonia in children: current challenges and future directions. J Infect. 2014;69(Suppl. 1):S87–90.
   PubMed Web of Science ®Google Scholar
• Esposito S, Principi N. Unsolved problems in the approach to pediatric community-acquired pneumonia. Curr Opin Infect Dis. 2012;25:286–291.
   PubMed Web of Science ®Google Scholar
• Jacobs MR, Dagan R. Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges. Semin Pediatr Infect Dis. 2004;15:5–20.
   PubMedGoogle Scholar
• World Health Organization. Recommendations for management of common childhood conditions, evidence for technical update of pocket book recommendations. Geneva: World Health Organization; 2012. Available at: http://www.who.int/maternal_child_adolescent/documents/management_childhood_conditions/en Accessed on: January 20, 2018.
   Google Scholar
• World Health Organization. Revised WHO classification and treatment of childhood pneumonia at health facilities. Available at: http://apps.who.int/iris/bitstream/10665/137319/1/9789241507813_eng.pdf Accessed on: January 20, 2018.
   Google Scholar
• Harris M, Clark J, Coote N, et al. British thoracic society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(Suppl 2):ii1–23.
   PubMedGoogle Scholar
• Esposito S, Cohen R, Domingo JD, et al. Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J. 2012;31:e78–85.
   PubMed Web of Science ®Google Scholar
• Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53:e25–76.
   PubMed Web of Science ®Google Scholar
• Esposito S, Daleno C, Prunotto G, et al. Impact of viral infections in children with community-acquired pneumonia: results of a study of 17 respiratory viruses. Influenza Other Respir Viruses. 2013;7:18–26.
   PubMed Web of Science ®Google Scholar
• Tramper-Stranders GA. Childhood community-acquired pneumonia: a review of etiology- and antimicrobial treatment studies. Paediatr Respir Rev. 2017 July 15: pii: S1526-0542(17)30070-2. Epub. DOI:10.1016/j.prrv.2017.06.013
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Prevention of community-acquired pneumonia with available pneumococcal vaccines. Int J Mol Sci. 2016;18:pii: E30.
   PubMed Web of Science ®Google Scholar
• Berg AS, Inchley CS, Aase A, et al. Etiology of pneumonia in a pediatric population with high pneumococcal vaccine coverage: a prospective study. Pediatr Infect Dis J. 2016;35:e69–75.
   PubMed Web of Science ®Google Scholar
• Friedland IR. Comparison of the response to antimicrobial therapy of penicillin-resistant and penicillin-susceptible pneumococcal disease. Pediatr Infect Dis J. 1995;14:885–890.
   PubMed Web of Science ®Google Scholar
• Cardoso MR, Nascimento-Carvalho CM, Ferrero F, et al. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch Dis Child. 2008;93:221–225.
   PubMed Web of Science ®Google Scholar
• Reeves DS, Bullock DW. The aminopenicillins: development and comparative properties. Infection. 1979;7(Suppl. 5):S425–33.
   PubMedGoogle Scholar
• Donà D, Luise D, Dalt LD, et al. Treatment of community-acquired pneumonia: are all countries treating children in the same way? A literature review. Int J Pediatr. 2017;2017:4239268.
   PubMedGoogle Scholar
• Rodrigues CMC. Challenges of empirical antibiotic therapy for community-acquired pneumonia in children. Curr Ther Res Clin Exp. 2017;84:e7–11.
   PubMed Web of Science ®Google Scholar
• Esposito S, Blasi F, Allegra L, et al. Use of antimicrobial agents for community-acquired lower respiratory tract infections in hospitalised children. Eur J Clin Microbiol Infect Dis. 2001;20:647–650.
   PubMed Web of Science ®Google Scholar
• Clark JE, Hammal D, Spencer D, et al. Children with pneumonia: how do they present and how are they managed? Arch Dis Chil. 2007;92:394–398.
   PubMed Web of Science ®Google Scholar
• Handy LK, Bryan M, Gerber JS, et al. Variability antibiotic prescribing for community-acquired pneumonia. Pediatrics. 2017;139:pii: e20162331.
   PubMed Web of Science ®Google Scholar
• Williams DJ, Edwards KM, Self WH, et al. Effectiveness of β-lactam monotherapy vs macrolide combination therapy for children hospitalized with pneumonia. JAMA Pediatr. 2017;171:1184–1191.
   PubMed Web of Science ®Google Scholar
• Nascimento-Carvalho CM, Xavier-Souza G, Vilas-Boas AL, et al. Evolution of acute infection with atypical bacteria in a prospective cohort of children with community-acquired pneumonia receiving amoxicillin. J Antimicrob Chemother. 2017;72:2378–2384.
   PubMed Web of Science ®Google Scholar
• Biondi E, McCulloh R, Alverson B, et al. Treatment of mycoplasma pneumonia: a systematic review. Pediatrics. 2014;133:1081–1090.
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Gavranich JB, Chang AB. Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children. Cochrane Database Syst Rev. 2015;1:CD004875.
   PubMedGoogle Scholar
• Farrell DJ, Couturier C, Hryniewicz W. Distribution and antibacterial susceptibility of macrolide resistance genotypes in Streptococcus pneumoniae: PROTEKT year 5 (2003–2004). Int J Antimicrob Agents. 2008;31:245–249.
   PubMed Web of Science ®Google Scholar
• Pan F, Han L, Huang W, et al. Serotype distribution, antimicrobial susceptibility, and molecular epidemiology of Streptococcus pneumoniae isolated from children in Shanghai, China. PLoS One. 2015;10:e0142892.
   PubMed Web of Science ®Google Scholar
• Xiao Y, Wei Z, Shen P, et al. Bacterial-resistance among outpatients of county hospitals in China: significant geographic distinctions and minor differences between central cities. Microbes Infect. 2015;17:417–425.
   PubMed Web of Science ®Google Scholar
• Xu X, Cai L, Xiao M, et al. Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates. Antimicrob Agents Chemother. 2010;54:1152–1159.
   PubMed Web of Science ®Google Scholar
• Schroeder MR, Stephens DS. Macrolide resistance in Streptococcus pneumoniae. Front Cell Infect Microbiol. 2016;21(6):98.
   Google Scholar
• Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;35:556–564.
   PubMed Web of Science ®Google Scholar
• Pérez-Trallero E, Marimon JM, Iglesias L, et al. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates. Emerg Infect Dis. 2003;9:1159–1162.
   PubMed Web of Science ®Google Scholar
• Bauer T, Ewig S, Marcos MA, et al. Streptococcus pneumoniae in community-acquired pneumonia. How important is drug resistance? Med Clin North Am. 2001;85:1367–1379.
   PubMed Web of Science ®Google Scholar
• Rudolph K, Bulkow L, Bruce M, et al. Molecular resistance mechanisms of macrolide-resistant invasive Streptococcus pneumoniae isolates from Alaska, 1986 to 2010. Antimicrob Agents Chemother. 2013;57:5415–5422.
   PubMed Web of Science ®Google Scholar
• Handy L, Gerber JS, Bryan M, et al. Comparative effectiveness of beta-lactams versus azithromycin for treatment of outpatient pediatric community-acquired pneumonia. Poster presented at IDWeek; October 4 8, 2017; San Diego, CA.
   Google Scholar
• Ambroggio L, Test M, Metlay JP, et al. Beta-lactam versus beta-lactam/macrolide therapy in pediatric outpatient pneumonia. Pediatr Pulmonol. 2016;51:541–548.
   PubMed Web of Science ®Google Scholar
• Leyenaar JK, Shieh MS, Lagu T, et al. Comparative effectiveness of ceftriaxone in combination with a macrolide compared with ceftriaxone alone for pediatric patients hospitalized with community-acquired pneumonia. Pediatr Infect Dis J. 2014;33:387–392.
   PubMed Web of Science ®Google Scholar
• Weiss AK, Hall M, Lee GE, et al. Adjunct corticosteroids in children hospitalized with community-acquired pneumonia. Pediatrics. 2011;127:e255–63.
   PubMed Web of Science ®Google Scholar
• Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. 2008;358:716–727.
   PubMed Web of Science ®Google Scholar
• Rello J, Lisboa T, Lujan M, et al. Severity of pneumococcal pneumonia associated with genomic bacterial load. Chest. 2009;136:832–840.
   PubMed Web of Science ®Google Scholar
• Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol. 2011;335:2–13.
   PubMed Web of Science ®Google Scholar
• Brouwer MC, McIntyre P, Prasad K, et al. Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;9:CD004405.
   Google Scholar
• Remmelts HH, Meijvis SC, Heijligenberg R, et al. Biomarkers define the clinical response to dexamethasone in community-acquired pneumonia. J Infect. 2012;65:25–31.
   PubMed Web of Science ®Google Scholar
• Luo Z, Luo J, Liu E, et al. Effects of prednisolone on refractory Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2014;49:377–380.
   PubMed Web of Science ®Google Scholar
• Wu YJ, Sun J, Zhang JH, et al. Clinical efficacy of adjuvant therapy with glucocorticoids in children with lobar pneumonia caused by Mycoplasma pneumoniae. Zhongguo Dang Dai Er Ke Za Zhi [Chin J Contemp Pediatr]. 2014;16:401–405.
   PubMedGoogle Scholar
• Nagy B, Gaspar I, Papp A, et al. Efficacy of methylprednisolone in children with severe community acquired pneumonia. Pediatr Pulmonol. 2013;48:168–175.
   PubMedGoogle Scholar
• Van Woensel JB, Van Aalderen WM, De Weerd W, et al. Dexamethasone for treatment of patients mechanically ventilated for lower respiratory tract infection caused by respiratory syncytial virus. Thorax. 2003;58:383–387.
   PubMed Web of Science ®Google Scholar
• Ambroggio L, Test M, Metlay JP, et al. Adjunct systemic corticosteroid therapy in children with community-acquired pneumonia in the outpatient setting. J Pediatric Infect Dis Soc. 2015;4:21–27.
   PubMed Web of Science ®Google Scholar
• Tamura A, Matsubara K, Tanaka T, et al. Methylprednisolone pulse therapy for refractory Mycoplasma pneumoniae pneumonia in children. J Infect. 2008;57:223–228.
   PubMed Web of Science ®Google Scholar
• Lee KY, Lee HS, Hong JH, et al. Role of prednisolone treatment in severe Mycoplasma pneumoniae pneumonia in children. Pediatr Pulmonol. 2006;41:263–268.
   PubMed Web of Science ®Google Scholar
• Tagarro A, Otheo E, Baquero-Artigao F, et al. Dexamethasone for parapneumonic pleural effusion: a randomized, double-blind, clinical trial. J Pediatr. 2017;185:117–123.
   PubMed Web of Science ®Google Scholar
• Mahant S, Long SS. Corticosteroids for children with parapneumonic effusion. J Pediatr. 2017;185:2–3.
   PubMedGoogle Scholar
• Moss WJ. Measles. Lancet. 2017;390:2490–2502.
   PubMed Web of Science ®Google Scholar
• Hemilä H. Vitamin C and infections. Nutrients. 2017;9:pii: E339.
   PubMedGoogle Scholar
• Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;1:CD000980.
   PubMed Web of Science ®Google Scholar
• Mullins AL, Van Rosendal SP, Briskey DR, et al. Variability in oxidative stress biomarkers following a maximal exercise test. Biomarkers. 2013;18:446–454.
   PubMed Web of Science ®Google Scholar
• Institute of medicine. Vitamin C. Dietary reference intakes for vitamin C, vitamin E, selenium and carotenoids. Washington DC: National Academy Press, 2000:95–185.
   Google Scholar
• Prietl B, Treiber G, Pieber TR, et al. Vitamin D and immune function. Nutrients. 2013;5:2502–2521.
   PubMed Web of Science ®Google Scholar
• Esposito S, Lelii M. Vitamin D and respiratory tract infections in childhood. BMC Infect Dis. 2015;15:487.
   PubMed Web of Science ®Google Scholar
• Haugen J, Basnet S, Hardang IM, et al. Vitamin D status is associated with treatment failure and duration of illness in Nepalese children with severe pneumonia. Pediatr Res. 2017;82:986–993.
   PubMed Web of Science ®Google Scholar
• Huang SJ, Wang XH, Liu ZD, et al. Vitamin D deficiency and the risk of tuberculosis: a meta-analysis. Drug Des Dev Ther. 2016;11:91–102.
   PubMed Web of Science ®Google Scholar
• Morcos MM, Gabr AA, Samuel S, et al. Vitamin D administration to tuberculous children and its value. Boll Chim Farm. 1998;137:157–164.
   PubMedGoogle Scholar
• Autier P, Mullie P, Macacu A, et al. Effect of vitamin D supplementation on non-skeletal disorders: a systematic review of meta-analyses and randomised trials. Lancet Diabetes Endocrinol. 2017;5:986–1004.
   PubMed Web of Science ®Google Scholar
• Xiao L, Xing C, Yang Z, et al. Vitamin D supplementation for the prevention of childhood acute respiratory infections: a systematic review of randomised controlled trials. Br J Nutr. 2015;114:1026–1034.
   PubMed Web of Science ®Google Scholar
• Aglipay M, Birken CS, Parkin PC, et al. Effect of high-dose vs. standard-dose wintertime vitamin D supplementation on viral upper respiratory tract infections in young healthy children. JAMA. 2017;318:245–254.
   PubMed Web of Science ®Google Scholar
• Manaseki-Holland S, Qader G, Isaq Masher M, et al. Effects of vitamin D supplementation to children diagnosed with pneumonia in Kabul: a randomised controlled trial. Trop Med Int Health. 2010;15:1148–1155.
   PubMed Web of Science ®Google Scholar
• Gupta P, Dewan P, Shah D, et al. Vitamin D supplementation for treatment and prevention of pneumonia in under-five children: a randomized double-blind placebo controlled trial. Indian Pediatr. 2016;53:967–976.
   PubMed Web of Science ®Google Scholar
• Choudhary N, Gupta P. Vitamin D supplementation for severe pneumonia – a randomized controlled trial. Indian Pediatr. 2012;49:449–454.
   PubMed Web of Science ®Google Scholar
• Kimball S, Vieth R, Dosch HM, et al. Cholecalciferol plus calcium suppresses abnormal PBMC reactivity in patients with multiple sclerosis. J Clin Endocrinol Metab. 2011;96:2826–2834.
   PubMed Web of Science ®Google Scholar
• Andıran N, Çelik N, Akça H, et al. Vitamin D deficiency in children and adolescents. J Clin Res Pediatr Endocrinol. 2012;4:25–29.
   PubMed Web of Science ®Google Scholar
• McCulloh RJ, Norton LE, Goldman JL. Extending antimicrobial stewardship to all hospitalized children: the time is now. Hosp Pediatr. 2017;7:559–561.
   PubMedGoogle Scholar
• McCulloh RJ, Andrea S, Reinert S, et al. Potential utility of multiplex amplification respiratory viral panel testing in the management of acute respiratory infection in children: a retrospective analysis. J Pediatr Infect Dis Soc. 2014;3:146–153.
   PubMedGoogle Scholar
• Fonseca TS, Vasconcellos ÂG, Gendrel D, et al. Recovery from childhood community-acquired pneumonia in a developing country: prognostic value of serum procalcitonin. Clin Chim Acta. 2017 Dec 16: pii: S0009–8981(17)30521–1 Epub. DOI:10.1016/j.cca.2017.12.021.
   PubMedGoogle Scholar
• Esposito S, Tagliabue C, Picciolli I, et al. Procalcitonin measurements for guiding antibiotic treatment in pediatric pneumonia. Respir Med. 2011;105:1939–1945.
   PubMed Web of Science ®Google Scholar
• Esposito S, Bianchini S, Gambino M, et al. Measurement of lipocalin-2 and syndecan-4 levels to differentiate bacterial from viral infection in children with community-acquired pneumonia. BMC Pulm Med. 2016;16:103.
   PubMed Web of Science ®Google Scholar